Search

Author/Creator Cimbora, Daniel

1. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Issue 3 (May 2021)

Authors:
Marignier, Romain; Bennett, Jeffrey L.; Kim, Ho Jin; Weinshenker, Brian G.; Pittock, Sean J.; Wingerchuk, Dean; Fujihara, Kazuko; Paul, Friedemann; Cutter, Gary R.; Green, Ari J.; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D.; Williams, Ian M.; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees...
Journal:
Neurology
Issue:
Volume 8:Issue 3(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Issue 10206 (12th October 2019)

Authors:
Cree, Bruce A C; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean M; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D; Drappa, Jorn; Barron, Gerard; Madani, Soraya; Ratchfo...
Journal:
Lancet
Issue:
Volume 394:Issue 10206(2019)
Page Start:
1352
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. (May 2022)

Authors:
Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 6(2022)
Page Start:
925
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Issue 1 (December 2016)

Authors:
Schiopu, Elena; Chatterjee, Soumya; Hsu, Vivien; Flor, Armando; Cimbora, Daniel; Patra, Kaushik; Yao, Wenliang; Li, Jing; Streicher, Katie; McKeever, Kathleen; White, Barbara; Katz, Eliezer; Drappa, Jorn; Sweeny, Sarah; Herbst, Ronald
Journal:
Arthritis research & therapy
Issue:
Volume 18:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. (November 2021)

Authors:
Cree, Bruce AC; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Williams, Ian M; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees, Willia...
Journal:
Multiple sclerosis
Issue:
Volume 27:Number 13(2021)
Page Start:
2052
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗